Latest news with #Afib
Yahoo
23-05-2025
- Business
- Yahoo
AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
MASON, Ohio, May 23, 2025--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference. AtriCure's management is scheduled to host a fireside chat on Monday, June 9, 2025, at 4:00 p.m. Eastern Standard Time. Interested parties may access a live audio webcast by visiting the "Investors" section of the company's website at About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications and post-operative pain management. AtriCure's Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure's Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure's cryoICE cryoSPHERE® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit or follow us on X (formerly Twitter) @AtriCure. View source version on Contacts Angie WirickAtriCure, Financial Officer(513) 755-5334awirick@ Marissa BychGilmartin GroupInvestor Relationsmarissa@
Business Wire
23-05-2025
- Business
- Business Wire
AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Goldman Sachs 46 th Annual Global Healthcare Conference. AtriCure's management is scheduled to host a fireside chat on Monday, June 9, 2025, at 4:00 p.m. Eastern Standard Time. Interested parties may access a live audio webcast by visiting the 'Investors' section of the company's website at About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe use AtriCure technologies for the treatment of Afib, reduction of Afib related complications and post-operative pain management. AtriCure's Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure's Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure's cryoICE cryoSPHERE® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit or follow us on X (formerly Twitter) @AtriCure.
Epoch Times
15-05-2025
- Health
- Epoch Times
Gum Disease Bacteria Carry Heart Risks, May Trigger Atrial Fibrillation
That nagging bleeding when you brush your teeth may not be just a dental problem—it could be endangering your heart. A new study suggests that the bacterium responsible for gingivitis may slip from infected gums into the bloodstream and infiltrate heart tissue, to increase the risk of irregular heart beats. Irregular heart beats are linked to increased risks of strokes and heart failure. How Gum Disease Attacks Your Heart The findings, recently published in the journal Researchers examined heart tissue from 68 human patients with AFib who had undergone heart surgery and found many of these patients had P. gingivalis in the left atrium of their heart, particularly in the hearts of those with severe gum disease. They also infected mice with P. gingivalis and subsequently found the bacteria inside their hearts as well. These mice were also six times more likely to develop abnormal heart rhythms, such as AFib, compared to mice that were not infected. Researchers pointed out that this study is the first showing clear evidence that P. gingivalis can enter the heart by bacteria leaving the mouth to enter the bloodstream. Related Stories 4/12/2024 2/3/2024 'The causal relationship between periodontitis and atrial fibrillation is still unknown, but the spread of periodontal bacteria through the bloodstream may connect these conditions,' study first author Shunsuke Miyauchi said in a P. gingivalis enters the blood stream via 'periodontal lesions and further translocates to the left atrium [of the heart],' Miyauchi added, noting that the more severe the periodontitis, the more bacteria were found in the heart. Once in the atrium, P. gingivalis can cause scar tissue formation in the heart, which increases the Afib risk, Miyauchi said. Therefore, he noted, periodontal treatment, which can block 'the gateway of P. gingivalis translocation,' may play an important role in AFib prevention and treatment. When the immune system fights gum infections, it releases chemicals that can leak into the blood and cause inflammation all over the body, harming organs including the heart. Harmful bacteria like P. gingivalis have been found in heart tissue, valves, and fatty plaques in arteries. Any bleeding in the gums is an indication of gingivitis, Dr. Jessica Pharar, a dentist and owner of Drs. Chin and Pharar Dentistry in Las Vegas, told The Epoch Times. 'If you see bright red angry looking gums, that is a good indication you are progressing more severe gingivitis,' she added. 'Patients who have other health issues, especially inflammatory diseases, are more prone to gingivitis,' Pharar said. 'Cleaning your mouth twice a day is imperative. Regular check ups at the dentist are essential to protect your overall dental health.' The Wider Impact of Gum Disease The researchers pointed out doctors have noticed for years that people with gum disease frequently have more heart problems and noted that a recent meta-analysis linked gum disease to a 30 percent higher chance of developing AFib. Globally, cases of AFib have 'The prevalence of gum disease continues to be an important public health problem in the United States as 2 in 5 adults are affected by some form of this disease,' Dr. Sandip Sachar, a dentist in New York City, told The Epoch Times. Untreated gum disease can impact overall health beyond just the heart. Pharar cautioned that wherever gingivitis bacteria settles, it can cause problems. Research has consistently linked chronic gum infections to a variety of systemic health Diabetes 'Gum disease and diabetes seem to have a bidirectional relationship,' Sachar said. 'Poor blood sugar control worsens gum disease, and untreated gum disease can increase blood sugar, complicating the overall management of diabetes.' Alzheimer's and Dementia Studies have shown a link between moderate or severe gum disease and an Other Conditions Some studies have linked gum disease to an increased risk of developing certain types of 'Gum disease has also been linked to rheumatoid arthritis, respiratory problems, liver disease, and adverse pregnancy outcomes,' Sachar said. 'Untreated gum disease has been associated with preterm birth and low birth weight. Inflammatory responses in the mouth can potentially affect fetal development.' 'Patients who get a joint replacement can infect their new joint if they don't have good dental health,' Pharar said. However, the condition can be prevented, treated, and even reversed by 'getting professional dental cleanings by a dentist at least twice a year, and maintaining gum health with brushing twice a day, and flossing daily,' Sachar added.
Yahoo
18-03-2025
- Health
- Yahoo
Smart Meter Announces US Launch of Atrial Fibrillation App Used by More than One Million Patients in Europe
TAMPA, Fla., March 18, 2025--(BUSINESS WIRE)--In an era when technology is transforming healthcare to make it accessible anytime, anywhere, Smart Meter, the leader in remote patient monitoring (RPM) solutions, has teamed up with FibriCheck to launch their groundbreaking Atrial Fibrillation (Afib) detection app in the U.S. Already used by over one million patients in Europe, this innovative app turns smartphones into potentially life-saving diagnostic tools, putting control of heart health right at users' fingertips. FibriCheck, an FDA-cleared mobile app, harnesses cutting-edge algorithms and the built-in camera on smartphones to detect irregular heart rhythms that may signal Afib—one of the leading causes of stroke and cardiovascular complications. With Smart Meter's seamless integration, healthcare professionals can now access real-time heart rhythm data through a secure and clinically validated platform, enabling faster intervention and improved patient outcomes. The Growing Urgency for Accessible Afib Detection Afib, an irregular and rapid heart rhythm, affects over 10 million Americans, many of whom are undiagnosed due to its intermittent nature and often symptomless onset. This partnership seeks to bridge that gap, democratizing access to critical heart health monitoring and revolutionizing how Americans manage their cardiovascular health. "Afib monitoring should not be confined to hospitals or expensive equipment," said Casey Pittock, CEO of Smart Meter. "FibriCheck offers an elegant, accessible solution, empowering individuals to proactively monitor their heart rhythms using only their smartphone." Game-Changing Features of FibriCheck: - FDA-cleared with proven accuracy through clinical trials- Instant results in just one minute- Requires no additional devices—just a smartphone- Offers valuable insights into heart rhythm trends to guide healthcare decisions How It Works By simply placing a finger over the smartphone's camera lens, users can perform a non-invasive heart rhythm check anytime, anywhere. The app's sophisticated algorithms analyze patterns and provide actionable data that could save lives. A Partnership with Far-Reaching Impacts "Partnering with Smart Meter is a big step toward making advanced heart health solutions more accessible in the U.S," said Lars Grieten, CEO of FibriCheck. "This collaboration strengthens our commitment to innovation and patient empowerment while ensuring reliable, evidence-based technology for better cardiovascular care. By expanding access to essential diagnostics, like digital heart rhythm monitoring, we're helping people monitor their heart health using their own smartphone devices." By offering this innovative app to its extensive network of RPM companies and healthcare providers, Smart Meter is paving the way for real-time Afib monitoring, personalized care, and earlier intervention. About FibriCheck FibriCheck's medically certified technology transforms consumer devices like smartphones into FDA-cleared medical tools for the detection and monitoring of atrial fibrillation and other arrhythmia issues without additional hardware or logistical challenges. Its AI-driven analysis of intermittent and remote PPG measurements provides real-time data to the Smart Meter platform, giving healthcare providers insights into heart rate, rhythm, and Afib characteristics, including symptom patterns. With over 1 million users and adoption across 70+ health systems in the U.S., E.U., U.K., Australia, and the Middle East, FibriCheck enhances clinical decision-making, reduces wait times and costs, and improves efficiency for both patients and providers. About Smart Meter, LLC Smart Meter is the premier technology infrastructure provider for Remote Patient Monitoring (RPM) and patient engagement. We reliably deliver millions of real-time vital health readings from over 300,000 patients using our proprietary FDA registered cellular devices through our exclusive AT&T private data network. Trusted by thousands of healthcare service providers, Smart Meter is revolutionizing the way health data supports patient well-being and care. Learn more at View source version on Contacts Media Contact Keith 336-509-8024
Yahoo
12-03-2025
- Business
- Yahoo
AtriCure to Host Analyst & Investor Day on March 26, 2025
MASON, Ohio, March 12, 2025--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today reaffirmed that the company will host an Analyst & Investor Day at its headquarters in Mason, Ohio on Wednesday, March 26, 2025 from 1:00 pm to 4:00 pm ET. "Our team is excited to highlight our leading portfolio of products and innovative pipeline for market expansion at our Analyst and Investor Day. We also look forward to bringing perspectives from key opinion leaders as well as sharing longer-term financial goals as we continue driving growth and expanded profitability," said Michael Carrel, President and Chief Executive Officer of AtriCure. Information on attending this event, as well as a live and archived webcast of the presentation and Q&A sessions, will be available on the "Investors" section of the company's website at About AtriCure AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 59 million people worldwide. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure's Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure's Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure's cryoICE cryoSPHERE® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visit or follow us on X @AtriCure. View source version on Contacts Angie WirickAtriCure, Financial Officer(513) 755-5334awirick@ Marissa BychGilmartin GroupInvestor Relations(415) 991-5386marissa@ Sign in to access your portfolio
